NCT06034158

Molecular Basis of Loss Aversion

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: Sir Run Run Shaw Hospital · Academic / Other
• Sex: All
• Age: 25 Years – 40 Years
• Healthy volunteers: Accepted

Summary

The goal of this clinical trial is to test the roles of dopamine and norepinephrine in decision making related to loss aversion in the healthy population. The main question it aims to answer is whether temporarily boosting dopamine activity or temporarily suppressing norepinephrine activity has an impact on processing of potential gains and losses in financial decision making, social decision making, transaction decision making and moral decision making. Accordingly, participants will complete four decision-making tasks, namely investment task, driving task, trading task, and die task, after taking madopar, propranolol or placebo. Participants' psychological traits and psychiatric symptoms will be assessed once they are enrolled before the first-session day.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	single-dose madopar, single-dose propranolol, and single-dose placebo by order	Participants will take madopar, propranolol, and placebo (orange juice) each once in three separate sessions. The interval between every two sessions will be at least 3 days.
DRUG	single-dose madopar, single-dose placebo, and single-dose propranolol by order	Participants will take madopar, placebo(orange juice), and propranolol each once in three separate sessions. The interval between every two sessions will be at least 3 days.
DRUG	single-dose propranolol, single-dose madopar, and single-dose placebo by order	Participants will take propranolol, madopar, and placebo(orange juice) each once in three separate sessions. The interval between every two sessions will be at least 3 days.
DRUG	single-dose propranolol, single-dose placebo, and single-dose madopar by order	Participants will take propranolol, placebo(orange juice), and madopar each once in three separate sessions. The interval between every two sessions will be at least 3 days.
DRUG	single-dose placebo, single-dose propranolol, and single-dose madopar by order	Participants will take placebo(orange juice), propranolol, and madopar each once in three separate sessions. The interval between every two sessions will be at least 3 days.
DRUG	single-dose placebo, single-dose madopar, and single-dose propranolol by order	Participants will take placebo(orange juice), madopar, and propranolol each once in three separate sessions. The interval between every two sessions will be at least 3 days.

Timeline

• Start date: 2023-09-18
• Primary completion: 2024-03-01
• Completion: 2024-09-01
• First posted: 2023-09-13
• Last updated: 2023-09-26

Locations

1 site across 1 country: China